Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Approach Could Allow Red Blood Cells to be Manufactured

XTALKS VITALS NEWS

Red Blood Cells

UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Share this!

March 27, 2017 | by Sarah Hand, M.Sc.

Despite the best efforts of organizations like the Red Cross to encourage adults to donate blood, shortages still occur around the world. The blood supply is often limited for individuals with rare blood types, and large-scale natural disasters can quickly deplete the supply of safe, useable blood.

Researchers have long been working on ways to generate red blood cells in vitro, however methods using stem cells have failed to generate a consistent, sustainable supply. UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

“We have demonstrated a feasible way to sustainably manufacture red cells for clinical use,” senior study author Dr. Jan Frayne, of the School of Biochemistry at the University of Bristol, told BBC News. “We've grown litres of it.”



According to the researchers, the immature red blood cells – known as reticulocytes – produced using this method show no measurable differences compared to cells cultured in the lab. The researchers published their findings in the journal, Nature Communications.

The next step for the researchers is to pair the technology with a manufacturing system capable of producing large quantities of the lab-grown red blood cells for clinical use. Since the technique is likely to be very expensive – at least at first – the blood cells generated will likely be destined for patients with very rare blood types.

“There is a bioengineering challenge,” said Professor David Anstee, of the Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant. “To produce that much at scale is quite a challenge, and really the next phase of our work is to look at methods of expanding the yield.”

The researcher have yet to transfuse the cultured red blood cells into patients, however safety studies are likely to begin before the end of the year. The researchers say that the red blood cells could have a number of other purposes, including being used to study blood diseases.

“The first therapeutic use of a cultured red cell product is likely to be for patients with rare blood groups,” said Anstee, “because suitable conventional red blood cell donations can be difficult to source.”


Keywords: Blood, Cell Culture, Clinical Supply


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.